A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group

G. N. Holland, W. C. Buhles Jr, B. Mastre and H. J. Kaplan
AIDS Unit, UCLA Uveitis Center, Jules Stein Eye Institute.

To evaluate more accurately the clinical response of cytomegalovirus retinopathy to ganciclovir, a system for the assessment of disease outcome was developed that uses retinal photographs and three factors: development of new lesions, enlargement of preexisting lesions, and change in retinal opacification of lesion borders. With this system a retrospective comparison was performed of 24 ganciclovir-treated patients and 17 untreated patients with cytomegalovirus retinopathy. A masked assessment showed disease progression in 10 treated patients (43%) during a median period of 22 days. In contrast, 16 untreated patients (94%) had progression of disease during a median period of 25 days. Comparison of treated and untreated eyes also suggests that treatment may prevent deterioration of visual acuity during the same period. This study supports the conclusions of previous uncontrolled studies that ganciclovir is beneficial in the treatment of patients with acquired immunodeficiency syndrome and cytomegalovirus retinopathy. It also demonstrates the utility of the proposed system for assessment of disease outcome that can be used in future studies of therapy for necrotizing viral retinopathies.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Use of Fluorescence Resonance Energy Transfer Hybridization Probes To Evaluate Quantitative Real-Time PCR for Diagnosis of Ocular Toxoplasmosis
Simon et al.
J. Clin. Microbiol. 2004;42:3681-3685.
ABSTRACT | FULL TEXT  

Risk of Vision Loss in Patients With Cytomegalovirus Retinitis and the Acquired Immunodeficiency Syndrome
Kempen et al.
Arch Ophthalmol 2003;121:466-476.
ABSTRACT | FULL TEXT  

Visual Loss in Patients With Cytomegalovirus Retinitis and Acquired Immunodeficiency Syndrome Before Widespread Availability of Highly Active Antiretroviral Therapy
Holbrook et al.
Arch Ophthalmol 2003;121:99-107.
ABSTRACT | FULL TEXT  

Photographic Measures of Cytomegalovirus Retinitis as Surrogates for Visual Outcomes in Treated Patients
Holbrook et al.
Arch Ophthalmol 2001;119:554-563.
ABSTRACT | FULL TEXT  

Retinal Detachment Risk in Cytomegalovirus Retinitis Related to the Acquired Immunodeficiency Syndrome
Kempen et al.
Arch Ophthalmol 2001;119:33-40.
ABSTRACT | FULL TEXT  

Risk Factors for Advancement of Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome
Holbrook et al.
Arch Ophthalmol 2000;118:1196-1204.
ABSTRACT | FULL TEXT  

Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis
Ambati et al.
Br. J. Ophthalmol. 1999;83:1153-1158.
ABSTRACT | FULL TEXT  

Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study
Mitchell et al.
Br. J. Ophthalmol. 1999;83:652-655.
ABSTRACT | FULL TEXT  

Guidelines for the Treatment of Cytomegalovirus Diseases in Patients With AIDS in the Era of Potent Antiretroviral Therapy: Recommendations of an International Panel
Whitley et al.
Arch Intern Med 1998;158:957-969.
ABSTRACT | FULL TEXT  

Immune Recovery Vitritis Associated With Inactive Cytomegalovirus Retinitis: A New Syndrome
Karavellas et al.
Arch Ophthalmol 1998;116:169-175.
ABSTRACT | FULL TEXT  

Clinical Failure of CMV Retinitis With Intravitreal Cidofovir Is Associated With Antiviral Resistance
Smith et al.
Arch Ophthalmol 1998;116:178-185.
ABSTRACT | FULL TEXT  

Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome
Jacobson
NEJM 1997;337:105-114.
FULL TEXT  

New Therapies for Cytomegalovirus Retinitis
Holland and Tufail
NEJM 1995;333:658-659.
FULL TEXT